Frank Laukien

Chairman, President & CEO, Bruker Corporation (parent), Nanostring Bruker Spatial Biology

Search every verified Frank Laukien interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Frank Laukien, chairman, president, and CEO of Bruker Corporation, has been active in discussions on cancer and evolution, as well as in corporate earnings calls. In October 2020, he organized and spoke at the Cancer & Evolution Symposium, where he described cancer as "inherently a real-time evolutionary or quasi-evolutionary phenomenon" and stated that this insight "has not yet entered the mainstream of oncology." He argued that the symposium "could mark an inflection point" for the field. During the symposium, Laukien advocated for a broad definition of evolution that includes epigenetic and non-genetic processes, saying "any molecules that have that can store biological information inherently become evolvable." He also suggested that the host immune system could serve as "the most sensitive detector" for early cancer detection. On Bruker's Q2 2020 earnings call in August 2020, Laukien reported that the company had generated $7 million in COVID-19 related testing revenues from liquid handling robots, nucleic acid extraction kits, and PCR assays, with plans to ramp up production in the second half of the year. He noted that the company expected "sequential improvements" in financial performance from Q2 to Q3, contingent on containing the second wave of infections. In a 2019 symposium for Matthias Mann, Laukien discussed the role of proteomic fingerprinting in clinical microbiology, calling it "a new gold standard" and predicted that proteomics would become "significantly, dramatically more important over the next 10 years."